Hims & Hers stops selling weight loss pill days after unveiling it

February 8, 2026 - 08:25

Hims & Hers has announced it will immediately stop selling its newly launched compounded semaglutide weight loss pill. The decision comes just days after the product's high-profile unveiling, marking a sudden reversal for the direct-to-consumer telehealth platform.

The company stated the move followed "constructive conversations with stakeholders across the industry." While no specific regulatory body was named, the announcement suggests the discussions involved concerns or clarifications regarding the pill's formulation and market introduction. Compounded semaglutide, the active ingredient in popular injectable drugs like Wegovy, exists in a regulatory gray area when formulated as a pill, as the FDA-approved versions are injectable only.

This pause leaves current customers in limbo. Hims & Hers has stated it will fulfill existing prescriptions for the oral medication but will not accept new orders. The company emphasized its continued commitment to providing weight loss solutions through its other established programs and medications. The future of this specific compounded pill offering remains uncertain, pending further internal review and potential dialogue with industry and regulatory partners. The swift withdrawal underscores the complex and rapidly evolving landscape of the telehealth weight management industry.